Unlocking the potential of
genomic medicine

2018 News Releases

Date Title
Toggle Summary03/09/2017
PHILADELPHIA, PA -- (Marketwired) -- 03/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) Top-line data from SAGA Phase 2/3 trial of AEVI-001 in adolescents with mGluR+ ADHD to be announced by end of Q1 Robust pipeline with data from several AEVI-001 signal finding studies expected in 2017 Aevi
Toggle Summary02/27/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/27/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA on Monday, March 6, 2016 at
Toggle Summary02/21/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/21/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that it has strengthened its discovery and research platform by extending its genomics collaboration with the Center for Applied Genomics (CAG) at Children's Hospital of
Toggle Summary02/15/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/15/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced that it will host an Investor Day with senior management and key opinion leaders to discuss AEVI-001 and opportunities in the ADHD market.
Toggle Summary02/09/2017
PHILADELPHIA, PA -- (Marketwired) -- 02/09/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that Michael F. Cola , President and Chief Executive Officer, will present at the Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at
Toggle Summary01/31/2017
PHILADELPHIA, PA -- (Marketwired) -- 01/31/17 -- Aevi Genomic Medicine, Inc. (NASDAQ: GNMX) (the Company) announced today that the first patient has been dosed in a Phase 1/2 clinical trial to assess the efficacy of its lead investigational drug, AEVI-001 (NFC-1), in children with 22q11.2 Deletion
Toggle Summary01/04/2017
Untitled Document PHILADELPHIA, PA--(Marketwired - Jan 4, 2017) - Aevi Genomic Medicine, Inc. (NASDAQ: GNMX ) Top-line results expected in Q1 2017 Aevi Genomic Medicine, Inc. (NASDAQ: GNMX ) (the Company) announced today that enrollment is complete in the SAGA (Study of Adolescent Glutamate
Toggle Summary12/15/2016
PHILADELPHIA , Dec. 15, 2016 /PRNewswire/ --  Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc.  Aevi Genomic Medicine (pronounced "AHH-vee") is a name inspired by the Old Norse language which means "life story" and reflects the
Toggle Summary11/22/2016
PHILADELPHIA, PA -- (Marketwired) -- 11/22/16 -- Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 30, 2016 at 11:00 AM EST at the
Toggle Summary11/09/2016
PHILADELPHIA, PA -- (Marketwired) -- 11/09/16 -- Medgenics, Inc. (NASDAQ: MDGN) today announced that Michael F. Cola , President and Chief Executive Officer, will present at the Jefferies London Healthcare Conference in London, UK on Thursday, November 17, 2016 at 10:40 a.m.